Interleukin23 in Systemic Lupus

NCT06713187 | Recruiting

• 1 other identifier: Soh_Med__24_11_09MS
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 2

Brief Summary

assement of interleukin 23 in serum of patients with systemic lupus erythematosus related interstial lung disease .

Conditions

Systemic Lupus Erythematosus Related Interstial Lung Disease

Outcome Measures

Primary Outcomes (1)

• interleukin 23

  level of interleukin 23 in Sera of patients with systemic lupus erythematosus using ELIZA

  2 years

Study Arms (3)

group 1

ACTIVE COMPARATOR

Patients with systemic lupus erythematosus without interstial lung disease.

Biological: interleukin 23

group2

ACTIVE COMPARATOR

Patients with systemic lupus erythematosus with interstial lung disease.

Biological: interleukin 23

group3

ACTIVE COMPARATOR

healthy control groups

Biological: interleukin 23

Interventions

interleukin 23 BIOLOGICAL

assessment of interleukin 23 in Sera of patients using ELIZA

group 1; group2; group3

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• patients with systemic lupus erythematous and patients with systemic lupus erythematosus with interstial lung disease.

You may not qualify if:

• patients with chest conditions rather than interstial lung disease \&who receiving biological blocking antibodies\& those treated with immunosuppressive drugs.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (2)

Sohag university hospital

Sohag, Egypt

RECRUITING

Sohag university

Sohag, Egypt

RECRUITING

Related Publications (4)

• Yap DY, Lai KN. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol. 2010;2010:365083. doi: 10.1155/2010/365083. Epub 2010 May 6.

  PMID: 20467470 BACKGROUND

• Haroon MM, Hegazy GA, Hassanien MA, Shaker O, Hussein WH. Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices. Biologics. 2023 Jan 18;17:1-9. doi: 10.2147/BTT.S389021. eCollection 2023.

  PMID: 36698375 BACKGROUND

• Sisto M, Lisi S. Interleukin-23 Involved in Fibrotic Autoimmune Diseases: New Discoveries. J Clin Med. 2023 Sep 1;12(17):5699. doi: 10.3390/jcm12175699.

  PMID: 37685766 BACKGROUND

• Senoo S, Taniguchi A, Itano J, Oda N, Morichika D, Fujii U, Guo L, Sunami R, Kanehiro A, Tokioka F, Yoshimura A, Kiura K, Maeda Y, Miyahara N. Essential role of IL-23 in the development of acute exacerbation of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2021 Nov 1;321(5):L925-L940. doi: 10.1152/ajplung.00582.2020. Epub 2021 Sep 15.

  PMID: 34524907 BACKGROUND

MeSH Terms

Interventions

Interleukin-23

Intervention Hierarchy (Ancestors)

Interleukins; Cytokines; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors

Central Study Contacts

Khadiga M Salem, resident doctor

CONTACT

01069152448; khadiga_mahmoud_post@med.sohag.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: resident doctor at clinical pathology department

Study Record Dates

• First Submitted: November 27, 2024
• First Posted: December 3, 2024
• Study Start: May 1, 2025
• Primary Completion: August 1, 2025
• Study Completion (Estimated): June 1, 2026
• Last Updated: December 3, 2024

Record last verified: 2024-11

Locations

EG (2)